BD Veritor™ At-Home and BD Veritor™ Professional

Exclusion Criteria

• •1\. Participants currently undergoing treatment and/or within the past thirty (30) days of the study, with medication to treat novel Coronavirus SARS-CoV-2 viral infections, which may include but is not limited to Remdesivir (Veklury)
• •2\. Participants receiving convalescent plasma therapy for SARS-CoV-2.
• •3\. Participants who have received antiviral medications for influenza within the previous 30 days.
• •4\. Participants who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit.
• •5\. The participant is currently receiving or has received within the past thirty (30) days of the study visit, an experimental biologic or drug including either treatment or therapy.
• •6\. Participants who have been previously enrolled in the study.
• •7\. History of frequent or difficult to control nosebleeds within the last fourteen (14) days.
• •8\. Participants who have tested positive for Flu A/B or SARS-CoV-2 within the last 28 days (excluding the day of enrollment in the study).
• •1\. Participants without the ability to read or write in the English Language
• •2\. Participants with prior medical or laboratory training.